Acadia Pharma (ACAD) Q2 Revs of $115.2M; Tops EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SWKS
9. FISV
10. CVS

Go back to Acadia Pharma (ACAD) Q2 Revs of $115.2M; Tops EPS by 4c

Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results

August 4, 2021 4:05 PM EDT

- 2Q21 net sales of $115.2 million, a 5% increase over 2Q20

- Fiscal year 2021 revenue guidance reduced to $480 to $515 million

- Type A meeting held with FDA regarding DRP; Acadia will continue discussion with FDA in another meeting later this year

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2021.

NUPLAZID performed well in the second quarter of 2021, highlighted by our ability to drive growth while still... More